Hongyao Liu

759 total citations · 1 hit paper
30 papers, 551 citations indexed

About

Hongyao Liu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Hongyao Liu has authored 30 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Hongyao Liu's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers), Occupational and environmental lung diseases (4 papers) and Liver physiology and pathology (3 papers). Hongyao Liu is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers), Occupational and environmental lung diseases (4 papers) and Liver physiology and pathology (3 papers). Hongyao Liu collaborates with scholars based in China, Vietnam and Saudi Arabia. Hongyao Liu's co-authors include Tinghong Ye, Cailing Gan, Zui Tan, Yuting Xie, Taixiong Xue, Yuqin Yao, Hongbao Sun, Qianyu Zhang, Yali Li and Wenya Yin and has published in prestigious journals such as Journal of Medicinal Chemistry, Biochemical Pharmacology and RSC Advances.

In The Last Decade

Hongyao Liu

30 papers receiving 545 citations

Hit Papers

Liver Fibrosis: Therapeut... 2021 2026 2022 2024 2021 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hongyao Liu China 11 191 156 133 112 75 30 551
Saijun Fan China 11 257 1.3× 62 0.4× 120 0.9× 61 0.5× 63 0.8× 32 581
Yang Ke China 14 250 1.3× 54 0.3× 112 0.8× 159 1.4× 75 1.0× 34 617
Jiaru Wang China 13 194 1.0× 80 0.5× 64 0.5× 35 0.3× 63 0.8× 38 457
Ya Tian China 7 234 1.2× 111 0.7× 90 0.7× 25 0.2× 59 0.8× 10 451
Noha A. Amin Egypt 12 267 1.4× 46 0.3× 82 0.6× 47 0.4× 51 0.7× 13 472
Fanhua Kong China 16 445 2.3× 119 0.8× 85 0.6× 70 0.6× 130 1.7× 40 786
Yuanbiao Guo China 15 288 1.5× 66 0.4× 92 0.7× 26 0.2× 100 1.3× 52 565
Hong Seok Choi South Korea 11 156 0.8× 66 0.4× 62 0.5× 27 0.2× 101 1.3× 24 484
Juji Dai China 11 388 2.0× 205 1.3× 74 0.6× 44 0.4× 123 1.6× 19 665
Siwei Xia China 14 222 1.2× 73 0.5× 184 1.4× 92 0.8× 29 0.4× 30 537

Countries citing papers authored by Hongyao Liu

Since Specialization
Citations

This map shows the geographic impact of Hongyao Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongyao Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongyao Liu more than expected).

Fields of papers citing papers by Hongyao Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongyao Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongyao Liu. The network helps show where Hongyao Liu may publish in the future.

Co-authorship network of co-authors of Hongyao Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Hongyao Liu. A scholar is included among the top collaborators of Hongyao Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongyao Liu. Hongyao Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Yue, Zui Tan, Wei Wei, et al.. (2025). Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment. European Journal of Medicinal Chemistry. 285. 117232–117232. 2 indexed citations
2.
Wei, Qun, Cailing Gan, Meng Sun, et al.. (2024). BRD4: an effective target for organ fibrosis. Biomarker Research. 12(1). 92–92. 9 indexed citations
3.
Yu, Yan, Hongyao Liu, Liping Yuan, et al.. (2024). Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis. Materials Today Bio. 25. 100980–100980. 8 indexed citations
4.
Liu, Hongyao, Yan Yu, Taixiong Xue, et al.. (2023). A nonenzymatic electrochemical sensor for the detection of hydrogen peroxide in vitro and in vivo fibrosis models. Chinese Chemical Letters. 35(3). 108574–108574. 6 indexed citations
6.
Liu, Hongyao & Jia Ni. (2023). Research on the influence of social support on college students' positive mental health. 4(8). 1 indexed citations
7.
Li, Zhongjian, et al.. (2022). A rare case of bladder cancer that metastasized to brain, heart, and lung lymph nodes benefited from immunotherapy. World Journal of Surgical Oncology. 20(1). 402–402. 4 indexed citations
8.
Wang, Yijie, Hongyao Liu, Wenzhen Li, et al.. (2022). Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis. European Journal of Medicinal Chemistry. 246. 114953–114953. 6 indexed citations
9.
Lin, Yue, Taixiong Xue, Zhihao Liu, et al.. (2022). Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents. European Journal of Medicinal Chemistry. 242. 114685–114685. 7 indexed citations
10.
Li, Yali, Liqun Wang, Qianyu Zhang, et al.. (2022). Blueberry Juice Attenuates Pulmonary Fibrosis via Blocking the TGF-β1/Smad Signaling Pathway. Frontiers in Pharmacology. 13. 825915–825915. 6 indexed citations
11.
Gan, Cailing, Yan Wang, Zhongzheng Xiang, et al.. (2022). Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro. Journal of Advanced Research. 51. 109–120. 27 indexed citations
12.
Tan, Zui, Hongbao Sun, Taixiong Xue, et al.. (2021). Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Frontiers in Cell and Developmental Biology. 9. 730176–730176. 153 indexed citations breakdown →
13.
Xue, Taixiong, Xingyu Qiu, Hongyao Liu, et al.. (2021). Epigenetic regulation in fibrosis progress. Pharmacological Research. 173. 105910–105910. 73 indexed citations
14.
Liu, Hongyao, Xiuli Wu, Cailing Gan, et al.. (2021). A novel multikinase inhibitor SKLB‐YTH‐60 ameliorates inflammation and fibrosis in bleomycin‐induced lung fibrosis mouse models. Cell Proliferation. 54(7). e13081–e13081. 20 indexed citations
15.
Zhang, Qianyu, Liqun Wang, Cailing Gan, et al.. (2020). Cryptotanshinone Induces Apoptosis and Inhibits Migration and Invasion in Human Hepatocellular Carcinoma Cells In Vitro. Natural Product Communications. 15(1). 6 indexed citations
16.
Wang, Liqun, Hongyao Liu, Cailing Gan, et al.. (2020). Galangin ameliorated pulmonary fibrosis in vivo and in vitro by regulating epithelial-mesenchymal transition. Bioorganic & Medicinal Chemistry. 28(19). 115663–115663. 27 indexed citations
17.
Zhu, Yongxia, Weiqiong Zuo, Lijuan Chen, et al.. (2019). Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. Biochemical Pharmacology. 169. 113610–113610. 36 indexed citations
18.
Gan, Cailing, Yali Li, Yan Yu, et al.. (2019). Natural product pectolinarigenin exhibits potent anti-metastatic activity in colorectal carcinoma cells in vitro and in vivo. Bioorganic & Medicinal Chemistry. 27(21). 115089–115089. 16 indexed citations
19.
Liu, Hongyao. (2012). Reversal effect and mechanism of osthole on the multidrug-resistance of human bladder cancer cells T24/ADM. China Modern Medicine. 4 indexed citations
20.
Liu, Hongyao. (2009). Research on Image Denoising Based on Wavelet Transform. Shuxue de shijian yu renshi. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026